FATE SEC Filing News — Fate Therapeutics, Inc.

Latest SEC filings for Fate Therapeutics, Inc. (FATE) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-28.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex…
Sector: Healthcare Industry: Biotechnology Market Cap: $224.7M
20
Total Filings
0
Bullish Classifications
4
Bearish Classifications
13
Insider Transactions
4
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for FATE currently lean bearish. Of the 20 filing records displayed, 4 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
FATE Filing Activity Snapshot 2026-05-21 — 2026-09-28
Insider Transactions (Form 4)
0 buys vs 4 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$108.1K
Valamehr Bahram (Director, President and CEO) · 2026-08-05
43,947 shares · Form 4
Form 144 Notices
2
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 13 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 13 filings in this group are Form 4s for Fate Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 13 insider filings shown, the breakdown is 9 compensation award and 4 open-market sale. 4 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×9
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×4
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Form 4 Open-market sale Insider Selling 2026-08-05

FATE insider TAHL CINDY (See Remarks) sold 38,800 shares (~$95.4K)

TAHL CINDY, listed as See Remarks at FATE THERAPEUTICS INC, reported an open-market sale of 38,800 FATE shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 38,800 $2.46 $95.4K
Filing: Form 4 (Insider Transaction) Insider: TAHL CINDY (See Remarks) Shares: 38,800 Est. Value: $95.4K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-05

FATE insider Valamehr Bahram (Director, President and CEO) sold 43,947 shares (~$108.1K)

Valamehr Bahram, listed as Director, President and CEO at FATE THERAPEUTICS INC, reported an open-market sale of 43,947 FATE shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 43,947 $2.46 $108.1K
Filing: Form 4 (Insider Transaction) Insider: Valamehr Bahram (Director, President and CEO) Shares: 43,947 Est. Value: $108.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

FATE insider Form 4 filed for equity award, exercise, or tax withholding

Redmile Group, LLC (Director, 10% Owner) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Option (Right to Buy) 87,900 — —
Filing: Form 4 (Insider Transaction) Insider: Redmile Group, LLC (Director, 10% Owner)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

FATE insider Form 4 filed for equity award, exercise, or tax withholding

Lee Michael Stewart (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Option (Right to Buy) 87,900 — —
Filing: Form 4 (Insider Transaction) Insider: Lee Michael Stewart (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

FATE insider Form 4 filed for equity award, exercise, or tax withholding

Xu Yuan (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Option (Right to Buy) 87,900 — —
Filing: Form 4 (Insider Transaction) Insider: Xu Yuan (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

FATE insider Form 4 filed for equity award, exercise, or tax withholding

Jooss Karin (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Option (Right to Buy) 87,900 — —
Filing: Form 4 (Insider Transaction) Insider: Jooss Karin (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

FATE insider Form 4 filed for equity award, exercise, or tax withholding

EPSTEIN ROBERT S (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Option (Right to Buy) 87,900 — —
Filing: Form 4 (Insider Transaction) Insider: EPSTEIN ROBERT S (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

FATE insider Form 4 filed for equity award, exercise, or tax withholding

Agarwal Shefali (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Option (Right to Buy) 87,900 — —
Filing: Form 4 (Insider Transaction) Insider: Agarwal Shefali (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

FATE insider Form 4 filed for equity award, exercise, or tax withholding

ABERNETHY MATT (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Option (Right to Buy) 87,900 — —
Filing: Form 4 (Insider Transaction) Insider: ABERNETHY MATT (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

FATE insider Form 4 filed for equity award, exercise, or tax withholding

RASTETTER WILLIAM H (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Option (Right to Buy) 87,900 — —
Filing: Form 4 (Insider Transaction) Insider: RASTETTER WILLIAM H (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

FATE insider Form 4 filed for equity award, exercise, or tax withholding

Hamill Laura (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Option (Right to Buy) 175,800 — —
Filing: Form 4 (Insider Transaction) Insider: Hamill Laura (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-05-21

FATE insider TAHL CINDY (See Remarks) sold 25,590 shares (~$48.1K)

TAHL CINDY, listed as See Remarks at FATE THERAPEUTICS INC, reported an open-market sale of 25,590 FATE shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 25,590 $1.88 $48.1K
Filing: Form 4 (Insider Transaction) Insider: TAHL CINDY (See Remarks) Shares: 25,590 Est. Value: $48.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-05-21

FATE insider Valamehr Bahram (Director, President and CEO) sold 28,946 shares (~$54.5K)

Valamehr Bahram, listed as Director, President and CEO at FATE THERAPEUTICS INC, reported an open-market sale of 28,946 FATE shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 28,946 $1.88 $54.5K
Filing: Form 4 (Insider Transaction) Insider: Valamehr Bahram (Director, President and CEO) Shares: 28,946 Est. Value: $54.5K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 2 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Fate Therapeutics, Inc. has 2 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-08-04

FATE Form 144 filed for proposed insider sale by TAHL CINDY (38,800 shares) ~$95.4K

TAHL CINDY filed a Form 144 with the SEC indicating intent to sell FATE (FATE THERAPEUTICS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: TAHL CINDY Shares: 38,800 Est. Value: $95.4K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-04

FATE Form 144 filed for proposed insider sale by Valamehr Bahram (43,947 shares) ~$108.1K

Valamehr Bahram filed a Form 144 with the SEC indicating intent to sell FATE (FATE THERAPEUTICS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Valamehr Bahram Shares: 43,947 Est. Value: $108.1K
View on SEC EDGAR → Open Filing Document →
Material Events 4 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 4 in this period for Fate Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-28

FATE filed 8-K — material company event

FATE THERAPEUTICS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-13

FATE filed 8-K — material company event

FATE THERAPEUTICS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-15

FATE filed 8-K — material company event

FATE THERAPEUTICS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-04

FATE filed 8-K — material company event

FATE THERAPEUTICS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Fate Therapeutics, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-13

FATE filed Quarterly Report (10-Q)

FATE THERAPEUTICS INC filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Fate Therapeutics, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on FATE. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — FATE SEC Filings

More Tools for FATE

FATE Full Stock Analysis FATE Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper FATE analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the FATE stock analysis page.

FATE Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer